US Patent 9694013 Therapeutically active compounds and their methods of use
Patent 9694013 was granted and assigned to Agios Pharmaceuticals on July, 2017 by the United States Patent and Trademark Office.
All edits
Edits on 7 Dec, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 6 Dec, 2023
Golden AI
Edits made to:
Article (+197 characters)
Article
Patent abstract
Provided are compounds useful for treating cancer and methods of treating cancer, for example an advanced solid tumor, such as a glioma, or angioimmunoblastic T-cell lymphoma (AITL).
Edits on 30 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Inventor Names
Samuel V. Agresta0
Edits on 14 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09694013 Therapeutically active compounds and their methods of use US Patent 9694013 Therapeutically active compounds and their methods of use
Infobox
Patent Number
096940130
Patent Number
96940130
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
096940130
Date of Patent
July 4, 2017
0Patent Application Number
148682830
Date Filed
September 28, 2015
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 13 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09694013 Therapeutically active compounds and their methods of use
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09694013
Date of patent
July 4, 2017
Patent application number
14868283
Date Filed
September 28, 2015
Patent primary examiner
Find more entities like US Patent 9694013 Therapeutically active compounds and their methods of use
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.